Reviewing medical records of young people with acute lymphoblastic leukemia in poorer countries
Looks back at records of young people with leukemia or lymphoma in low-income countries.
Plain-language title generated from the registry record
Registry title: CAYA Cancer Retrospective Cohort Study
Key facts
- Where
- San Pedro Sula and Tegucigalpa, HondurasSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, teenagers and young adults who were diagnosed with cancer in the last 15 years and were treated at a participating centre. Their medical records are reviewed.
- Age
- 0 to 21 years at the time of diagnosis.
- Sex
- All sexes can join.
- Disease stage
- Any type of confirmed cancer, diagnosed within the 15 years before the site's activation date. The study focuses on acute lymphoblastic leukemia and lymphoblastic lymphoma.
- Earlier treatment
- Must have received substantial anti-cancer treatment at the participating center, such as chemotherapy, surgery, radiation therapy or immunotherapy.
Main reasons for not taking part
- Visited the centre only for a consultation, with no anti-cancer treatment there
- Visited the centre only for pathology, radiology or other diagnostic tests, with no treatment
- Medical records not available or not accessible for review
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 21 years old?
Source: NCT07246213, who can take part
Where in Honduras
- Hospital Mario Catarino RivasSan Pedro Sula, HondurasTaking people
- Hospital EscuelaTegucigalpa, HondurasTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Resonance, Inc.
- Trial code
- NCT07246213
- Record updated
- 29 September 2026
- Original description
Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies.Read full original descriptionShow less
Improving Cancer Outcomes for Children, Adolescents, and Young Adults: A Multicenter Retrospective Cohort Study on Treatment Failure and Toxicity in Low- and Middle-Income Countries
Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies.
Acute lymphoblastic leukemia(ALL)/lymphoblastic lymphoma(LBL), for example, is one of the greatest success stories in pediatric oncology, however, such improvements are not evenly distributed worldwide, and the outcomes for leukemia patients are poorer in LMICs compared to HICs, primarily due to reduced access to quality healthcare.
This study aims to assess cancer treatment outcomes in LMICs, focusing on acute lymphoblastic leukemia/lymphoblastic lymphoma. The findings will inform future studies to implement evidence-based interventions that improve care quality and reduce treatment failures through targeted strategies.
Inclusion: Subjects must meet all the following criteria to be included in this registry:; Participants must be willing and able to provide informed consent prior to enrollment in the registry; For minors or individuals unable to provide informed consent, assent must be obtained along with consent from a legal guardian; Note: Exemption applies to this criterion when waiver of informed consent/assent is granted by Institutional Review Board(IRB)/Independent Ethics Committee(IEC)/Competent Authorities(CAs); A confirmed diagnosis of any type of cancer within the 15 years prior to the site's activation date; Age 0 to 21 years at the time of diagnosis; Received substantial anti-cancer treatment at the participating center, including but not limited to:; Chemotherapy; Surgery; Radiation therapy; Immunotherapy; Medical records are available and accessible for review.
Exclusion: Subjects meeting any of the following criteria will be excluded from this registry:; Patients who only visited the participating center for:; Consultation without subsequent primary anti-cancer treatment at the participating center; Pathology, radiology, or other diagnostic evaluations without treatment.